[{"company":"Matinas BioPharma","sponsor":"BTIG","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Matinas BioPharma"},{"company":"Inositec AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inositec AG"},{"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Aerami Therapeutics Inc","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Vectura Ltd"},{"company":"Cato Research","sponsor":"JanOne","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Cato Research"},{"company":"Regenerative Care Network","sponsor":"Organicell Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin\u2122 for Patients with Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Regenerative Care Network"},{"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Announces Data Sowing Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Verve Therapeutics"},{"company":"Verve Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","amount":"$94.0 million","upfrontCash":"Undisclosed","newsHeadline":"Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Verve Therapeutics"},{"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Arrowhead Pharmaceuticals"},{"company":"Tenaya Therapeutics","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$106.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Tenaya Therapeutics"},{"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Verve Therapeutics"},{"company":"Heartseed","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"$598.0 million","upfrontCash":"$55.0 million","newsHeadline":"Heartseed and Novo Nordisk Enter Into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"},{"company":"CSIR-Indian Institute of Chemical Technology","sponsor":"Marc Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CSIR-CDRI Signs Agreement with Marc Labs to Develop Drug for Heart Attack and Stroke","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"CSIR-Indian Institute of Chemical Technology"},{"company":"Heartseed","sponsor":"UTokyo Innovation Platform","pharmaFlowCategory":"D","amount":"$37.0 million","upfrontCash":"Undisclosed","newsHeadline":"Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Heartseed"},{"company":"LQT Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"LQT Therapeutics Announces Closing of US$19M Series A Financing","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"LQT Therapeutics"},{"company":"Help Therapeutics","sponsor":"Ming Bioventures","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Help Therapeutics Completes Series C Financing of 25 Million Dollars","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Help Therapeutics"},{"company":"Verve Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Verve Therapeutics"}]
Details:
Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Lead Product(s):
Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Aerami
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
June 08, 2020
Details:
VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single A-to-G base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production, which subsequently lowers LDL-C levels in the blood.
Lead Product(s):
VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: VERVE-101
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 04, 2022
Details:
The financing will help the company conduct and complete clinical trials of its fully independent intellectual property development pipeline, iPSC heart cell injection, and will initiate clinical studies of immune cell therapy based on iPSC technology within the next year.
Lead Product(s):
iPSC-derived Cardiomyocyte
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Ming Bioventures
Deal Size: $25.0 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
November 27, 2021
Details:
LQTT is advancing a series of in- licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1).
Lead Product(s):
Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Amplitude Ventures
Deal Size: $19.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
August 10, 2021
Details:
The agreement has been signed for the development of a synthetic compound S-007-867 as modulator of blood coagulation cascade, in particular as inhibitor of collagen induced platelet aggregation.
Lead Product(s):
S007-867
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: S007-867
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Marc Laboratories
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
June 12, 2021
Details:
Heartseed plans to use the new funds to accelerate the initiation of global clinical trial of our lead asset, HS-001
for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.
Lead Product(s):
Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: HS-001
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
UTokyo Innovation Platform
Deal Size: $37.0 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
June 11, 2021
Details:
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan in the second half of 2021.
Lead Product(s):
Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: HS-001
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Novo Nordisk
Deal Size: $598.0 million
Upfront Cash: $55.0 million
Deal Type: Collaboration
June 01, 2021
Details:
Disease model of HeFH, the company’s mouse surrogate version of VERVE-101 produced similar and robust amounts of PCSK9 editing in the liver, above 50%, at doses of 0.05, 0.1 and 0.5 mg/kg administered as a single dose to wild-type and heterozygous LDLR knockout mice.
Lead Product(s):
VERVE-101
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: VERVE-101
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 11, 2021
Details:
The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platform.
Lead Product(s):
AAV-gene therapy
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
RTW Investments
Deal Size: $106.0 million
Upfront Cash: Undisclosed
Deal Type: Series C Financing
March 01, 2021
Details:
By inhibiting ANGPTL3, Arrowhead’s investigational ARO-ANG3 is designed to reduce triglycerides and decrease LDL cholesterol in patients with mixed dyslipidemia.
Lead Product(s):
ARO-ANG3
Therapeutic Area: Cardiology/Vascular Diseases
Product Name: ARO-ANG3
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 25, 2021
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
Contact Supplier
